Literature DB >> 15454126

Drug-induced autoimmunity.

Nancy J Olsen1.   

Abstract

Drug induced autoimmune syndromes have been recognized for many years. The classical presentation is that of drug-induced lupus, a generally milder version of the idiopathic disorder that is associated with production of antihistone antibodies. This pattern is now changing, in part due to the many new drugs that have been introduced into clinical practice for treatment of autoimmune diseases, including both conventional pharmaceuticals and biologicals. The number and complexity of drug-induced autoimmune syndromes has increased, and many are now associated with autoantibodies that have been classically defined as limited to idiopathic disease states. Furthermore, some of these drug-induced syndromes have life-threatening complications, so that recognition of drug-induced disease has become more difficult at a time when it is more urgent to establish a correct diagnosis. Many reports are limited to case descriptions, and few controlled investigations have been carried out. Nevertheless, it is possible to derive an approach to considering possible mechanisms by which these processes may take place. This chapter will consider these proposed mechanisms, using some of the implicated drugs to illustrate possible pathogenetic pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454126     DOI: 10.1016/j.berh.2004.05.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  12 in total

1.  Acrylamine-induced autoimmune phenomena.

Authors:  Bruce Rothschild
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

2.  A role for muscarinic receptors in neutrophil extracellular trap formation and levamisole-induced autoimmunity.

Authors:  Carmelo Carmona-Rivera; Monica M Purmalek; Erica Moore; Meryl Waldman; Peter J Walter; H Martin Garraffo; Karran A Phillips; Kenzie L Preston; Jonathan Graf; Mariana J Kaplan; Peter C Grayson
Journal:  JCI Insight       Date:  2017-02-09

3.  Analysis of autoantibody profiles in two asbestiform fiber exposure cohorts.

Authors:  Jean C Pfau; Christopher Barbour; Brad Black; Kinta M Serve; Marvin J Fritzler
Journal:  J Toxicol Environ Health A       Date:  2018-09-19

4.  A case of polymyositis and vasculitis induced by ovulation induction therapy with gonadotropin-releasing hormone.

Authors:  Ivica Lazúrová; Jana Angelovicová; Jana Petríková; Anna Calfová; Mária Oetterová; Marián Svajdler
Journal:  Clin Rheumatol       Date:  2010-05-02       Impact factor: 2.980

5.  Propylthiouracil-induced autoimmune syndromes: 11 case report.

Authors:  Rui Wu; Rongheng Li
Journal:  Rheumatol Int       Date:  2010-12-07       Impact factor: 2.631

6.  Carbimazole-induced lupus.

Authors:  Ihteshamul Haq; Michael D Sosin; Simon Wharton; Anindya Gupta
Journal:  BMJ Case Rep       Date:  2013-02-06

7.  Pegylated interferon alpha-2B induced lupus in a patient with chronic hepatitis B virus infection: case report.

Authors:  Sema Yilmaz; Kadriye Akar Cimen
Journal:  Clin Rheumatol       Date:  2009-08-04       Impact factor: 3.650

8.  Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events.

Authors:  Tigran Makunts; Keith Burkhart; Ruben Abagyan; Peter Lee
Journal:  PLoS One       Date:  2022-02-10       Impact factor: 3.240

9.  Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink.

Authors:  Hilda J I de Jong; Jan Willem Cohen Tervaert; Arief Lalmohamed; Frank de Vries; Rob J Vandebriel; Henk van Loveren; Olaf H Klungel; Tjeerd P van Staa
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

10.  Clinical Characteristics of Hydralazine-induced Lupus.

Authors:  Homa Timlin; Michael Wu; Monica Crespo-Bosque; Duvuru Geetha; Ashley Ingolia; Uzma Haque; Marilyn C Towns; Thomas Grader-Beck
Journal:  Cureus       Date:  2019-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.